Berberine counteracts enhanced IL-8 expression of AGS cells induced by evodiamine

Life Sci. 2013 Nov 19;93(22):830-9. doi: 10.1016/j.lfs.2013.09.010. Epub 2013 Sep 22.

Abstract

Aims: Although showing an anti-tumor activity, evodiamine also up-regulated IL-8 production of human gastric cancer AGS cells. This study aimed to assess this effect and to examine whether co-administration with berberine counteracts it.

Main methods: MTT assay was used to assess the cell proliferation and adhesive ability. Flow cytometry was performed to measure the cell cycle distribution. Wound healing assay was used to detect the migration ability of cells. IL-8 production was determined by ELISA. Levels of mRNA expression of IL-8, VCAM-1 and ICAM-1 were measured by real-time PCR. Molecular pathways involved were evaluated by ELISA and western-blotting methods.

Key findings: Evodiamine triggered proliferative inhibition and cell cycle arrest, and decreased migration of AGS cells. IL-8 expression and the adhesive ability of AGS cells to HUVECs were significantly increased by evodiamine, but were inhibited after being co-treated with berberine in AGS cells. As IL-8 was neutralized, increased adhesion of AGS cells to HUVECs induced by evodiamine was abolished. Berberine significantly suppressed the up-regulation of VCAM-1 and the down-regulation of ICAM-1 induced by evodiamine. Evodiamine provoked IL-8 secretion via ERK1/2, SAPK/JNK, JAK2 and AP-1 pathways which could be counteracted by berberine.

Significance: Although showing anti-proliferative and anti-migratory activities in AGS cells, evodiamine displayed a potential tendency to promote metastasis of gastric cancer cells by increasing IL-8 secretion and adhesion molecules. However, berberine could counteract the side-effect and simultaneously keep anti-proliferative and anti-migratory properties of evodiamine on AGS cells, which reduces the risk to use evodiamine in therapy of gastric cancers.

Keywords: AGS cells; Adhesion; Berberine; Evodiamine; IL-8.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents, Phytogenic / pharmacology
  • Berberine / pharmacology*
  • Cell Adhesion / drug effects
  • Cell Cycle / drug effects
  • Cell Movement / drug effects
  • Cell Proliferation / drug effects
  • Chemokines / genetics
  • Chemokines, CXC
  • Chromones / pharmacology
  • Human Umbilical Vein Endothelial Cells / drug effects
  • Humans
  • Imidazoles / pharmacology
  • Intercellular Adhesion Molecule-1 / genetics
  • Interleukin-8 / genetics
  • Interleukin-8 / metabolism*
  • Morpholines / pharmacology
  • Pyridines / pharmacology
  • Quinazolines / adverse effects
  • Quinazolines / pharmacology*
  • Signal Transduction / drug effects
  • Stomach Neoplasms / drug therapy
  • Stomach Neoplasms / metabolism
  • Stomach Neoplasms / pathology*
  • Tumor Cells, Cultured

Substances

  • Antineoplastic Agents, Phytogenic
  • CXCL17 protein, human
  • Chemokines
  • Chemokines, CXC
  • Chromones
  • ICAM1 protein, human
  • Imidazoles
  • Interleukin-8
  • Morpholines
  • Pyridines
  • Quinazolines
  • Berberine
  • Intercellular Adhesion Molecule-1
  • 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one
  • evodiamine
  • SB 203580